|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In all components (bilateral serous borderline tumors, low-grade serous carcinoma and mesonephric-like adenocarcinoma), an identical KRAS mutation was detected (NM_004985.4): c.35G>A, p.(G12D) proving a clonal association between the serous and mesonephric-like components and excluding a collision neoplasm.
|
30575604 |
2020 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In all components (bilateral serous borderline tumors, low-grade serous carcinoma and mesonephric-like adenocarcinoma), an identical KRAS mutation was detected (NM_004985.4): c.35G>A, p.(G12D) proving a clonal association between the serous and mesonephric-like components and excluding a collision neoplasm.
|
30575604 |
2020 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway.
|
30304546 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results showed that the AZ628 and BP-1-102 combination showed strongly synergistic effects on KRAS(G12D) H838, KRAS(G12S) H292 and KRAS(G12V) H441 cells and significantly enhanced the inhibition of cell proliferation <i>in vitro</i> and tumor growth <i>in vivo</i> by promoting apoptosis compared with one inhibitor alone.
|
31484165 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway.
|
30304546 |
2019 |
|
rs121913530
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Liquid biopsy profiling of circulating tumor DNA revealed the acquisition of KRAS proto-oncogene, GTPase (<i>KRAS</i>) p.G12C mutation, indicating the occurrence of another resistance mechanism to erlotinib.
|
31186738 |
2019 |
|
rs121913530
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results showed that the AZ628 and BP-1-102 combination showed strongly synergistic effects on KRAS(G12D) H838, KRAS(G12S) H292 and KRAS(G12V) H441 cells and significantly enhanced the inhibition of cell proliferation <i>in vitro</i> and tumor growth <i>in vivo</i> by promoting apoptosis compared with one inhibitor alone.
|
31484165 |
2019 |
|
rs121913530
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While ameloblastomas show BRAF p.V600E mutations, adenomatoid odontogenic tumours harbour either KRAS p.G12R or p.G12 V. The lack of understanding of the core molecular changes involved in tumour initiation and progression represents a critical barrier to developing new strategies for cancer detection and prevention.
|
31543246 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, whilst oncogenic KRAS mutation might activate Yap in other cell types, we could find no evidence for this in myoblasts because the expression of KRAS G12V expression did not change Yap/Taz activity in myoblasts and there was a limited overlap in gene expression between KRAS G12V and YAP1 S127A-driven tumours.
|
30353028 |
2018 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
When the assay was applied to tumor samples with known KRAS or NRAS mutations (G12A, G12D, G12V, and G13D), RAS-mutant and wild-type peptides were successfully detected in 11 of 13 biopsy samples.
|
29684684 |
2018 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Tumors harboring mutant KRAS-G12 V had a significantly higher PD-L1 expression compared to other tumors (p = 0.044), while mutant KRAS-G12D tumors showed an increase in the density of CD66b+ cells (p = 0.001).
|
29858030 |
2018 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Next generation sequencing found only the KRAS G12D and RNF43 G659Vfs*41 mutations were retained from the pre-treatment tumor in the treatment-resistant tumor.
|
30458888 |
2018 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Three of the four tumors had a BRAF (V600E) driver mutation, an EGFR (del E746-T751/S752V) driver mutation, or driver mutations in both EGFR (E709G) and KRAS (G12V).
|
29624782 |
2018 |
|
rs121913530
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Compared to patients with c.38G > A (rs112445441, p.G13D), patients with c.*4066delA (rs560890523) and c.38G > A (rs112445441, p.G13D) presented more aggressive tumors with highly invasive features.
|
27256640 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results showed that 21 of 34 tumors with high-grade TB had KRAS mutations (P=.001) and KRAS G12D and PIK3CA exon 9 variants were significantly associated with high-grade TB (P=.002 and .006, respectively); furthermore, tumors with KRAS mutations in exons 3 and 4 tended to have lymphovascular tumor emboli and perineural invasion (P=.044 and .049, respectively).
|
28188750 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Polymerase chain reaction identified a Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>) G12V mutation in the tumor.
|
28932588 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Importantly, intratumoral injection of the adenoviruses with pro-drug treatment specifically and significantly impeded the growth of xenografted tumors harboring KRAS G12V through a trans-splicing reaction with the target RNA.
|
28153088 |
2017 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This unique trial will yield prospective information on the efficacy of cetuximab and whether this is further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer: the "quadruple wild type", which may 'superselect' for tumours sensitive to EGFR-inhibition, and the rare KRAS G13D mutated tumours, which are also postulated to be sensitive to the drug.
|
27246726 |
2016 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
|
27358379 |
2016 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether the efficacy of anti-EGFR mAbs for mCRC differs between tumours harbouring a KRAS G13D mutation (KRAS G13D) and KRAS mutations other than G13D (other KRAS MT).
|
26812186 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumo</span>r burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The karyotype is highly complex, with a hypotriploid to hypertriploid modal number (3n+/-) (52 to 77 chromosomes); low level of HER2 gene amplification, TP53 deletion, gain of AURKA were identified; K-RAS G12D mutation were maintained from primary tumor to MT-CHC01 cells.
|
26486326 |
2016 |